Eriocalyxin B 生物活性：作用机制综述,Natural Product Communications

当前位置： X-MOL 学术 › Nat. Prod. Commun. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Eriocalyxin B 生物活性：作用机制综述
Natural Product Communications ( IF 1.5 ) Pub Date : 2019-08-01 , DOI: 10.1177/1934578x19868598
Ammara Riaz ₁ , Bisma Saleem ₁ , Ghulam Hussain ₂ , Iqra Sarfraz ₁ , Bushra Nageen ₁ , Rabia Zara ₁ , Maleeha Manzoor ₁ , Azhar Rasul ₁

Affiliation

天然产物是生物活性化合物的丰富来源，自古以来一直是人类更安全的首选药物。Eriocalyxin B 是一种 ent-Kaurene 二萜类化合物，已从传统中草药 Isodon eriocalyx 中提取。实验数据支持 EriB 的抗癌和抗炎活性。这种天然实体对乳腺癌、胰腺癌、白血病、卵巢癌、肺癌、膀胱癌和结肠直肠癌具有抗癌作用。EriB 具有通过促进细胞凋亡、阻止细胞周期和调节细胞信号通路来抑制癌细胞增殖的能力。EriB 对癌细胞中信号通路的调节涉及各种凋亡相关因子（Bak、Bax、caspase、XIAP、survivin 和 Beclin-1）、转录因子（核因子 kappa B [NF-κB]、STAT3 , Janus 活化激酶 2、Notch、AP-1 和 lκBα）、酶（环氧合酶 2、基质金属蛋白酶 2 [MMP-2]、MMP-9 和聚（ADP-核糖）聚合酶）、细胞因子和蛋白激酶（丝裂原活化蛋白激酶和 ERK1/2)。这篇综述提出，EriB 为治愈癌症提供了一个新的机会，但补充研究以及临床前试验是有效弄清楚其生物学和药理学应用的必要条件。

"点击查看英文标题和摘要"

Eriocalyxin B Biological Activity: A Review on Its Mechanism of Action

Natural products, a rich source of bioactive chemical compounds, have served humans as a safer drug of choice since times. Eriocalyxin B, an ent-Kaurene diterpenoid, has been extracted from a traditional Chinese herb Isodon eriocalyx. Experimental data support the anticancer and anti-inflammatory activities of EriB. This natural entity exhibits anticancer effects against breast, pancreatic, leukemia, ovarian, lung, bladder, and colorectal cancer. EriB has capability to inhibit the proliferation of cancer cells by prompting apoptosis, arresting cell cycle, and modulating cell signaling pathways. The regulation of signaling pathways in cancerous cells by EriB involves the modulation of various apoptosis-related factors (Bak, Bax, caspases, XIAP, survivin, and Beclin-1), transcriptional factors (nuclear factor kappa B [NF-κB], STAT3, Janus-activated kinase 2, Notch, AP-1, and lκBα), enzymes (cyclooxygenase 2, matrix metalloproteinase 2 [MMP-2], MMP-9, and poly (ADP-ribose) polymerase), cytokines, and protein kinases (mitogen-activated protein kinase and ERK1/2). This review proposes that EriB supplies a novel opportunity for the cure of cancer but supplementary investigations along with preclinical trials are obligatory to effectively figure out its biological and pharmacological applications.

更新日期：2019-08-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南